Do ACE inhibitors and ARBs have specific renoprotective effects?
Claire Braybrook
This article has no abstract so we have provided the first paragraph of the full text.
In addition to their capacity to lower systemic blood pressure, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) are thought to have specific renoprotective effects in patients with diabetic and nondiabetic nephropathy. Some guidelines advocating the use of these drugs in renal disease, however, base their recommendations on the results of placebo-controlled trials with no clinically relevant endpoints.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
